p.45 抽出テキスト

June 18/25, 2019 Circulation. 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625 e1126

CLINICAL STATEMENTS AND GUIDELINES myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437–45. S3.2.1-4.	 US Food and Drug Administration. Drugs@FDA: FDA Approved

Drug Products. Available at: https://www.accessdata.fda.gov/scripts/ cder/daf/ Accessed January 8, 2018. S3.2.1-5.	 Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207. S3.2.1-6.	 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9. S3.2.1-7.	 Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–22. S3.2.1-8.	 Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001–9. S3.2.1-9.	 Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–7. S3.2.1-10.	Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–57. S3.2.1-11.	MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebocontrolled trial. Lancet. 2002;360:23–33. S3.2.1-12.	Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–59. S3.2.1-13.	Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504. S3.2.1-14.	LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–35. S3.2.1-15.	Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368:1155–63. S3.2.1-16.	Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2021–31. S3.2.1-17.	Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670–81. S3.2.1-18.	Naito R, Miyauchi K, Daida H. Racial differences in the cholesterollowering effect of statin. J Atheroscler Thromb. 2017;24:19–25. S3.2.1-19.	Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532–61. S3.2.1-20.	American College of Cardiology. American College of Cardiology

LDL-C Manager. Available at: http://tools.acc.org/ldl. Accessed January 8, 2018.

3.2.2 Nonstatin Therapies

S3.2.2-1.	 Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97. S3.2.2-2.	 Kashani A, Sallam T, Bheemreddy S, et al. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am J Cardiol. 2008;101:1606–13. S3.2.2-3.	 Khan AR, Bavishi C, Riaz H, et al. Increased risk of adverse neurocognitive outcomes with proprotein convertase subtilisin-kexin type 9 inhibitors. Circ Cardiovasc Qual Outcomes. 2017;10: e003153. S3.2.2-4.	 Robinson JG, Rosenson RS, Farnier M, et al. Safety of very low lowdensity lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials. J Am Coll Cardiol. 2017;69:471–82. S3.2.2-5.	 Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clini-

cal outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22. S3.2.2-6.	 Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a ran-

domized trial of evolocumab. N Engl J Med. 2017;377:633–43.

3.2.3 Nonstatin Add-on Drugs to Statin Therapy

S3.2.3-1.	 Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372:2387–97. S3.2.3-2.	 Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1–full report. J Clin Lipidol. 2015;9:129–69. S3.2.3-3.	 Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36:1186–94. S3.2.3-4.	 Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of

evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500–9.

4 PATIENT MANAGEMENT GROUPS

4.1 Secondary ASCVD Prevention

S4.1-1.	 Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–59. S4.1-2.	 Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin. 2002;18:220–8. S4.1-3.	 Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670–81. S4.1-4.	 Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532–61. S4.1-5.	 Group HPSC. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20 536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45:645–54.; discussion 53–4. S4.1-6.	 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9. S4.1-7.	 Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001–9. S4.1-8.	 Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–57. S4.1-9.	 Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153–62. S4.1-10.	 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:23–33. S4.1-11.	 Knopp RH, d’Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478–85. S4.1-12.	 Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipidlowering disease management clinics: the alliance study. J Am Coll Cardiol. 2004;44:1772–9. S4.1-13.	 Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for pre-

vention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. Jama. 2002;287:3215–22.

Downloaded from http://ahajournals.org by on October 7, 2026